Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study

BACKGROUND: The once-daily oral combination of daclatasvir (DCV) and sofosbuvir (SOF), with or without ribavirin (RBV), is effective and well tolerated in patients with hepatitis C virus (HCV). However, further field-practice studies are necessary to investigate the effectiveness and safety of the D...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Drugs Context
Главные авторы: Sacco, Rodolfo, Messina, Vincenzo, Gentilucci, Umberto Vespasiani, Adinolfi, Luigi Elio, Ascione, Antonio, Barbarini, Giorgio, Barlattani, Angelo, Cariti, Giuseppe, Cozzolongo, Raffaele, Fimiani, Basilio, Francavilla, Ruggiero, Furlan, Caterina, Garrucciu, Giovanni, Iovinella, Vincenzo, Rinaldi, Luca, Marignani, Massimo, Begini, Paola, Palitti, Valeria Pace, Pellicelli, Adriano M, Scifo, Gaetano, Facciorusso, Antonio, Giacomelli, Luca, Shah, Aashni, Bertino, Gaetano, Perazzo, Serena, Bresci, Giampaolo, Izzi, Antonio
Формат: Artigo
Язык:Inglês
Опубликовано: BioExcel Publishing Ltd 2020
Предметы:
Original Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7747789/
https://ncbi.nlm.nih.gov/pubmed/33408749
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.2020-4-11
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы